Modified Glasgow Prognostic Score As a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette-Guerin Immunotherapy

Background: A systemic inflammatory marker, the modified Glasgow prognostic score (mGPS), could predict outcomes in non-muscle-invasive bladder cancer (NIMBC). We aimed to investigate the predictive power of mGPS in oncological outcomes in HG/G3 T1 NMIBC patients undergoing Bacillus Calmette-Guérin (BCG) therapy.

Methods: We retrospectively reviewed patient's medical data from multicenter institutions. A total of 1382 patients with HG/G3 T1 NMIBC have been administered adjuvant intravesical BCG therapy, every week for 3 weeks given at 3, 6, 12, 18, 24, 30 and 36 months. The analysis of mGPS for recurrence and progression was performed using multivariable and univariable Cox regression models.

Results: During follow-up, 659 patients (47.68%) suffered recurrence, 441 (31.91%) suffered progression, 156 (11.28%) died of all causes, and 67 (4.84%) died of bladder cancer. At multivariable analysis, neutrophil to lymphocyte ratio [hazard ratio (HR): 7.471; = 0.0001] and erythrocyte sedimentation rate (ESR) (HR: 0.706; = 0.006 were significantly associated with recurrence. mGPS has no statistical significance for progression ( = 0.076). Kaplan-Meier survival analysis showed a significant difference in survival among patients from different mGPS subgroups. Five-year OS was 93% (CI 95% 92-94), in patients with mGPS 0, 82.2% (CI 95% 78.9-85.5) in patients with mGPS 1 and 78.1% (CI 95% 60.4-70) in mGPS 2 patients. Five-year CSS was 98% (CI 95% 97-99) in patients with mGPS 0, 90% (CI 95% 87-94) in patients with mGPS 1, and 100% in mGPS 2 patients. Limitations are applicable to a retrospective study.

Conclusions: mGPS may have the potential to predict recurrence in HG/G3 T1 NMIBC patients, but more prospective, with large cohorts, studies are needed to study the influence of systemic inflammatory markers in prediction of outcomes in NMIBC for a definitive conclusion.

Citing Articles

Loss of MK2 Enhances Radiation-Mediated Apoptosis in Bladder Cancer.

Morgan D, Berggren K, Millington G, Smith H, Spiess C, Hixon M World J Oncol. 2024; 15(6):871-881.

PMID: 39697425 PMC: 11650613. DOI: 10.14740/wjon1945.

Prognostic value of neutrophil-to-lymphocyte ratio in patients with non-muscle-invasive bladder cancer with intravesical Bacillus Calmette-Guérin immunotherapy: a systematic review and meta-analysis.

Huang J, Lin L, Mao D, Hua R, Guan F Front Immunol. 2024; 15:1464635.

PMID: 39507536 PMC: 11538002. DOI: 10.3389/fimmu.2024.1464635.

Evaluation of serum fibronectin levels and fibronectin gene polymorphism in patients receiving intravesical BCG therapy for non-muscle invasive bladder cancer and its prognostic value.

Nebioglu A, Tanriverdi R, Basaranoglu M, Saylam B, Ulusoy E, Bozlu M BMC Urol. 2024; 24(1):210.

PMID: 39342212 PMC: 11438143. DOI: 10.1186/s12894-024-01592-8.

Urologist's role on smoking cessation counseling in patients presenting with asymptomatic hematuria: single academic institution experience.

Nakamura F, Tranthem L, Barefoot T, Johnson S, Goedde M, Choi K Transl Androl Urol. 2024; 13(8):1372-1377.

PMID: 39280679 PMC: 11399034. DOI: 10.21037/tau-23-592.

The upregulation of POLR3G correlates with increased malignancy of bladder urothelium.

Liu X, Zhu L, Li D, Chen X Eur J Med Res. 2024; 29(1):381.

PMID: 39039528 PMC: 11265097. DOI: 10.1186/s40001-024-01980-8.

References

Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat E . EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2016; 71(3):447-461. DOI: 10.1016/j.eururo.2016.05.041. View

Chou W, Yeh K, Peng M, Chen J, Wang H, Lin Y . Development and Validation of a Prognostic Score to Predict Survival in Adult Patients With Solid Tumors and Bone Marrow Metastases. Medicine (Baltimore). 2015; 94(23):e966. PMC: 4616467. DOI: 10.1097/MD.0000000000000966. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Kamat A, Sylvester R, Bohle A, Palou J, Lamm D, Brausi M . Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group. J Clin Oncol. 2016; 34(16):1935-44. PMC: 5321095. DOI: 10.1200/JCO.2015.64.4070. View

Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F . Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol. 2016; 71(1):96-108. DOI: 10.1016/j.eururo.2016.06.010. View

Sylvester R, van der Meijden A, Oosterlinck W, Witjes J, Bouffioux C, Denis L . Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006; 49(3):466-5. DOI: 10.1016/j.eururo.2005.12.031. View

Cambier S, Sylvester R, Collette L, Gontero P, Brausi M, van Andel G . EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin. Eur Urol. 2015; 69(1):60-9. DOI: 10.1016/j.eururo.2015.06.045. View

Vartolomei M, Ferro M, Cantiello F, Lucarelli G, Di Stasi S, Hurle R . Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer. Clin Genitourin Cancer. 2018; 16(6):445-452. DOI: 10.1016/j.clgc.2018.07.003. View

Miyake M, Morizawa Y, Hori S, Marugami N, Iida K, Ohnishi K . Integrative Assessment of Pretreatment Inflammation-, Nutrition-, and Muscle-Based Prognostic Markers in Patients with Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy. Oncology. 2017; 93(4):259-269. DOI: 10.1159/000477405. View

10.

Ferro M, DI Mauro M, Cimino S, Morgia G, Lucarelli G, Abu Farhan A . Systemic combining inflammatory score (SCIS): a new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer. Transl Androl Urol. 2021; 10(2):626-635. PMC: 7947442. DOI: 10.21037/tau-20-1272. View

11.

Werntz R, Smith Z, Packiam V, Smith N, Steinberg G . The Impact of Lymphovascular Invasion on Risk of Upstaging and Lymph Node Metastasis at the Time of Radical Cystectomy. Eur Urol Focus. 2018; 6(2):292-297. DOI: 10.1016/j.euf.2018.09.019. View

12.

Schuettfort V, DAndrea D, Quhal F, Mostafaei H, Laukhtina E, Mori K . A panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma. BJU Int. 2021; 129(2):182-193. PMC: 9291893. DOI: 10.1111/bju.15379. View

13.

Mbeutcha A, Shariat S, Rieken M, Rink M, Xylinas E, Seitz C . Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer. Urol Oncol. 2016; 34(11):483.e17-483.e24. DOI: 10.1016/j.urolonc.2016.05.013. View

14.

Ferro M, de Cobelli O, Buonerba C, Di Lorenzo G, Capece M, Bruzzese D . Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy: A Multicenter Experience. Medicine (Baltimore). 2015; 94(42):e1861. PMC: 4620818. DOI: 10.1097/MD.0000000000001861. View

15.

Uhlig A, Strauss A, Seif Amir Hosseini A, Lotz J, Trojan L, Schmid M . Gender-specific Differences in Recurrence of Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus. 2017; 4(6):924-936. DOI: 10.1016/j.euf.2017.08.007. View

16.

Gakis G, Todenhofer T, Renninger M, Schilling D, Sievert K, Schwentner C . Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score. BJU Int. 2011; 108(11):1800-5. DOI: 10.1111/j.1464-410X.2011.10234.x. View

17.

Hilmy M, Campbell R, Bartlett J, McNicol A, Underwood M, McMillan D . The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic infiltration and COX-2 expression and survival in patients with transitional cell carcinoma of the urinary bladder. Br J Cancer. 2006; 95(9):1234-8. PMC: 2360556. DOI: 10.1038/sj.bjc.6603415. View

18.

Vartolomei M, Porav-Hodade D, Ferro M, Mathieu R, Abufaraj M, Foerster B . Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): A systematic review and meta-analysis. Urol Oncol. 2018; 36(9):389-399. DOI: 10.1016/j.urolonc.2018.05.014. View

19.

Qayyum T, McArdle P, Hilmy M, Going J, Orange C, Seywright M . A prospective study of the role of inflammation in bladder cancer. Curr Urol. 2014; 6(4):189-93. PMC: 3783284. DOI: 10.1159/000343537. View

20.

Kimura S, D Andrea D, Soria F, Foerster B, Abufaraj M, Vartolomei M . Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer. Urol Oncol. 2018; 37(3):179.e19-179.e28. DOI: 10.1016/j.urolonc.2018.11.005. View